Daclizumab Is More Effective in Reducing Relapse Rates in Multiple Sclerosis Patients Than Interferon Beta-1a

Journal of pharmacology & clinical research
doi 10.19080/jpcr.2017.03.555601
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Juniper Publishers

Related search

Serum S100B in Primary Progressive Multiple Sclerosis Patients Treated With Interferon-Beta-1a

Journal of Negative Results in BioMedicine
GeneticsPharmacologyMolecular BiologyBiochemistryMedicineToxicologyPharmaceutics
2004English

Pregnancy Outcomes in Multiple Sclerosis Following Subcutaneous Interferon Beta-1a Therapy

Multiple Sclerosis
Neurology
2011English

Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated With Interferon Beta 1a by 1h-NMR Spectroscopy

Neurotherapeutics
NeurologyPharmacology
2019English

Treatment Recommendations for Interferon-Beta in Multiple Sclerosis

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1999English

T-Cell Interferon Gamma Receptor Binding in Interferon Beta-1b–Treated Patients With Multiple Sclerosis

Archives of Neurology
1999English

Prm89 - Database Analysis of a PSP (Patient Support Program) for Patients Using Interferon Beta-1a for Relapsing Multiple Sclerosis in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Relapse in Multiple Sclerosis

British Medical Journal
Medicine
2015English

The Effect of Interferon-Beta on Oxidative Stress in Patients With Multiple Sclerosis

Annals of the College of Medicine, Mosul
2018English

Glutathione in Multiple Sclerosis: More Than Just an Antioxidant?

Multiple Sclerosis
Neurology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy